Cargando…

Budesonide MMX for the Induction of Remission of Mild to Moderate Ulcerative Colitis: A Pooled Safety Analysis

BACKGROUND AND AIMS: Cumulative safety and tolerability of budesonide MMX, a once-daily oral corticosteroid for inducing mild to moderate ulcerative colitis remission, was examined. METHODS: Data from three randomized, double-blind, placebo-controlled, phase II or III studies [budesonide MMX 9mg, 6m...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lichtenstein, Gary R., Travis, Simon, Danese, Silvio, D’Haens, Geert, Moro, Luigi, Jones, Richard, Huang, Michael, Ballard, E. David, Bagin, Robert, Hardiman, Yun, Collazo, Raul, Sandborn, William J.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2015
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4736820/ https://www.ncbi.nlm.nih.gov/pubmed/26094251 http://dx.doi.org/10.1093/ecco-jcc/jjv101

Ejemplares similares

Induction of clinical and colonoscopic remission of mild–to–moderate ulcerative colitis with budesonide MMX 9 mg: pooled analysis of two phase 3 studies
por: Sandborn, W. J., et al.
Publicado: (2015)

Once-daily budesonide MMX in active, mild-to-moderate ulcerative colitis: results from the randomised CORE II study
por: Travis, Simon P L, et al.
Publicado: (2014)

Effectiveness of budesonide MMX (Cortiment) for the treatment of mild-to-moderate active ulcerative colitis: study protocol for a prospective multicentre observational cohort study
por: Danese, Silvio, et al.
Publicado: (2016)

Randomised trial of once- or twice-daily MMX mesalazine for maintenance of remission in ulcerative colitis
por: Kamm, M A, et al.
Publicado: (2008)

Budesonide MMX in the Treatment of Ulcerative Colitis: Current Perspectives on Efficacy and Safety
por: Maconi, Giovanni, et al.
Publicado: (2021)

Assessment of the effectiveness of Budesonide MMX(®) for active, mild-to-moderate ulcerative colitis in the Polish sub-group of the CORE Practice prospective multi-centre observational study
por: Jesionowski, Maciej, et al.
Publicado: (2023)

The safety of vedolizumab for ulcerative colitis and Crohn's disease
por: Colombel, Jean-Frédéric, et al.
Publicado: (2017)

Comparative Outcomes of Budesonide MMX versus Prednisolone for Ulcerative Colitis: Results from a British Retrospective Multi-Centre Real-World Study
por: Rosiou, Konstantina, et al.
Publicado: (2021)

Efficacy and safety of oral beclomethasone dipropionate and budesonide MMX versus 5-aminosalicylates or placebo in ulcerative colitis: a systematic review and meta-analysis
por: Barberio, Brigida, et al.
Publicado: (2023)

Practical Primer Addressing Real-World Use Scenarios of Subcutaneous Vedolizumab in Ulcerative Colitis and Crohn’s Disease: Post Hoc Analyses of VISIBLE Studies
por: Sandborn, William J, et al.
Publicado: (2023)

Budesonide Multi-matrix for the Treatment of Patients with Ulcerative Colitis
por: Lichtenstein, Gary R.
Publicado: (2015)

Once-daily MMX mesalamine for the treatment of mild-to-moderate ulcerative colitis
por: Kedia, Prashant, et al.
Publicado: (2007)

Ulcerative Colitis Remission Status After Induction With Mesalazine Predicts Maintenance Outcomes: the MOMENTUM Trial
por: Rubin, David T., et al.
Publicado: (2016)

Update on the management of ulcerative colitis: treatment and maintenance approaches focused on MMX(®) mesalamine
por: Nanda, Kavinderjit, et al.
Publicado: (2012)

Patient considerations in the management of ulcerative colitis: role of once-daily MMX mesalamine
por: Zandman, Daniel B, et al.
Publicado: (2009)

Health-Related Quality of Life and Work-Related Outcomes for Patients With Mild-to-Moderate Ulcerative Colitis and Remission Status Following Short-Term and Long-Term Treatment With Multimatrix Mesalamine: A Prospective, Open-Label Study
por: Yarlas, Aaron, et al.
Publicado: (2018)

Ulcerative Colitis: Shifting Sands
por: D’Haens, Geert R. A. M., et al.
Publicado: (2019)

Update on the management of ulcerative colitis: treatment and maintenance approaches focused on MMX(®) mesalamine. [Corrigendum]
por: Nanda, K, et al.
Publicado: (2013)

Budesonide Multimatrix Is Efficacious for Mesalamine-refractory, Mild to Moderate Ulcerative Colitis: A Randomised, Placebo-controlled Trial
por: Rubin, David T., et al.
Publicado: (2017)

Upadacitinib Induction and Maintenance Therapy Improves Abdominal Pain, Bowel Urgency, and Fatigue in Patients With Ulcerative Colitis: A Post Hoc Analysis of Phase 3 Data
por: Danese, Silvio, et al.
Publicado: (2023)

Exposure‐Response Characterization of Tofacitinib Efficacy in Moderate to Severe Ulcerative Colitis: Results From Phase II and Phase III Induction and Maintenance Studies
por: Mukherjee, Arnab, et al.
Publicado: (2022)

Corrigendum: Budesonide Multimatrix Is Efficacious for Mesalamine-refractory, Mild to Moderate Ulcerative Colitis: A Randomised, Placebo-controlled Trial
por: Rubin, David T, et al.
Publicado: (2017)

High prevalence of ulcerative appendicitis in patients with ulcerative colitis
por: Heuthorst, Lianne, et al.
Publicado: (2021)

Clinical Pharmacokinetic and Pharmacodynamic Considerations in the Treatment of Ulcerative Colitis
por: Berends, Sophie E., et al.
Publicado: (2018)

Intestinal Ultrasound to Assess Disease Activity in Ulcerative Colitis: Development of a novel UC-Ultrasound Index
por: Bots, Steven, et al.
Publicado: (2021)

Assessing the Clinical and Endoscopic Efficacy of Extended Treatment Duration with Different Doses of Mesalazine for Mild-to-Moderate Ulcerative Colitis beyond 8 Weeks of Induction
por: D’Haens, Geert, et al.
Publicado: (2023)

Prognostic Value of Colonic Tissue and Blood Eosinophils in Ulcerative Colitis
por: Haasnoot, Maria L, et al.
Publicado: (2022)

Middle-term prognosis in patients with ulcerative colitis who achieved clinical and endoscopic remission by budesonide rectal foam
por: Naganuma, Makoto, et al.
Publicado: (2019)

Association Between Proposed Definitions of Clinical Remission/Response and Well-Being in Patients With Crohn’s Disease
por: Sandborn, William J, et al.
Publicado: (2021)

Budesonide Foam Has a Favorable Safety Profile for Inducing Remission in Mild-to-Moderate Ulcerative Proctitis or Proctosigmoiditis
por: Rubin, David T., et al.
Publicado: (2015)

Population pharmacokinetics of subcutaneous infliximab CT‐P13 in Crohn’s disease and ulcerative colitis
por: Hanzel, Jurij, et al.
Publicado: (2021)

MMX(®) technology and its applications in gastrointestinal diseases
por: Nardelli, Silvia, et al.
Publicado: (2017)

Adalimumab maintains remission of Crohn's disease after up to 4 years of treatment: data from CHARM and ADHERE
por: Panaccione, R, et al.
Publicado: (2013)

Mirikizumab-Induced Transcriptome Changes in Ulcerative Colitis Patient Biopsies at Week 12 Are Maintained Through Week 52
por: Johnson, Travis, et al.
Publicado: (2023)

Mirikizumab Regulates Genes Involved in Ulcerative Colitis Disease Activity and Anti-TNF Resistance: Results From a Phase 2 Study
por: Steere, Boyd, et al.
Publicado: (2023)

Expression of Concern: Middle-term prognosis in patients with ulcerative colitis who achieved clinical and endoscopic remission by budesonide rectal foam
Publicado: (2023)

Tofacitinib for the Treatment of Ulcerative Colitis: An Integrated Summary of up to 7.8 Years of Safety Data from the Global Clinical Programme
por: Sandborn, William J, et al.
Publicado: (2022)

Changes in health-related quality of life and work-related outcomes for patients with mild-to-moderate ulcerative colitis receiving short-term and long-term treatment with multimatrix mesalamine: a prospective, open-label study
por: Willian, Mary Kaye, et al.
Publicado: (2018)

Randomised clinical study: discrepancies between patient‐reported outcomes and endoscopic appearance in moderate to severe ulcerative colitis
por: Jharap, B., et al.
Publicado: (2015)

A145 EFFICACY AND SAFETY OF UPADACITINIB MAINTENANCE THERAPY IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: RESULTS FROM A RANDOMIZED PHASE 3 STUDY
por: Panaccione, R, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_th1uoaqac4trn9lkpi0gios9ui